Drug Trial Radar · NCT07223203
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Feb 3, 2026
Primary completion
Dec 27, 2027
Study completion Jun 12, 2031
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Oct 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Conditions
- Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
- hATTR-PN
Interventions
NucresiranDrug
Nucresiran 300 mg administered SC q6M
VutrisiranDrug
Vutrisiran 25 mg administered SC q3M
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9Time frame: Baseline and Month 9
Locations
61 sites in 22 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Aurora, Colorado · Recruiting
Clinical Trial Site
Chicago, Illinois · Recruiting
Clinical Trial Site
Baltimore, Maryland · Recruiting
Clinical Trial Site
Boston, Massachusetts · Recruiting
Clinical Trial Site
Rochester, Minnesota · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
Chapel Hill, North Carolina · Recruiting
Clinical Trial Site
Nashville, Tennessee · Recruiting
Clinical Trial Site
Dallas, Texas · Recruiting
Clinical Trial Site
Houston, Texas · Recruiting
Clinical Trial Site
Belgrano, Argentina · Recruiting
Clinical Trial Site
Rosario, Argentina · Recruiting
Clinical Trial Site
Darlinghurst, Australia · Recruiting
Clinical Trial Site
Woolloongabba, Australia · Recruiting
Clinical Trial Site
Ribeirão Preto, Brazil · Recruiting
Clinical Trial Site
Rio de Janeiro, Brazil · Recruiting
Clinical Trial Site
Rio de Janeiro, Brazil · Recruiting
Clinical Trial Site
Salvador, Brazil · Recruiting
Clinical Trial Site
São Paulo, Brazil · Recruiting
Clinical Trial Site
Vancouver, Canada · Recruiting
Clinical Trial Site
Égkomi, Cyprus · Recruiting
Clinical Trial Site
Créteil, France · Recruiting
Clinical Trial Site
Le Kremlin-Bicêtre, France · Recruiting
Clinical Trial Site
Marseille, France · Recruiting
Clinical Trial Site
Berlin, Germany · Recruiting
Clinical Trial Site
Heidelberg, Germany · Recruiting
Clinical Trial Site
Münster, Germany · Recruiting
Clinical Trial Site
Athens, Greece · Recruiting
Clinical Trial Site
Heraklion, Greece · Recruiting
Clinical Trial Site
Dublin, Ireland · Recruiting
Clinical Trial Site
Florence, Italy · Recruiting
Clinical Trial Site
Milan, Italy · Recruiting
Clinical Trial Site
Padova, Italy · Recruiting
Clinical Trial Site
Pavia, Italy · Recruiting
Clinical Trial Site
Roma, Italy · Recruiting
Clinical Trial Site
Bunkyo C, Japan · Recruiting
Clinical Trial Site
Kumamoto, Japan · Recruiting
Clinical Trial Site
Matsumoto-shi, Japan · Recruiting
Clinical Trial Site
Suita, Japan · Recruiting
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.